MoonLake Immunotherapeutics (MLTX)
Automate Your Wheel Strategy on MLTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MLTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLTX
- Rev/Share 0.0016
- Book/Share 6.5247
- PB 6.0531
- Debt/Equity 0.1855
- CurrentRatio 21.111
- ROIC -0.2523
- MktCap 2476132443.0
- FreeCF/Share -2.2159
- PFCF -17.6713
- PE -16.9519
- Debt/Assets 0.1479
- DivYield 0
- ROE -0.0013
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MLTX | Wolfe Research | Peer Perform | Outperform | -- | $61 | May 19, 2025 |
| Initiation | MLTX | RBC Capital Mkts | -- | Outperform | -- | $67 | March 18, 2025 |
| Upgrade | MLTX | Goldman | Neutral | Buy | $62 | $82 | Jan. 17, 2025 |
| Downgrade | MLTX | Wolfe Research | Outperform | Peer Perform | -- | -- | Aug. 26, 2024 |
News
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Read More
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Read More
About MoonLake Immunotherapeutics (MLTX)
- IPO Date 2020-10-20
- Website https://www.moonlaketx.com
- Industry Biotechnology
- CEO Dr. Jorge Santos da Silva Ph.D.
- Employees 100